Jingrong Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jingrong Lin has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Yanjun Zheng
Shanghai Key Laboratory of Molecular Imaging, Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China
3 shared publications- Jian Ma
Department of Cardiology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Lian Xu
State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).
2 shared publications - Ping-Jin Gao
State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).
2 shared publications - Xiao-Hui Chen
State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).
2 shared publications - Ze-Bei Zhang
State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1963378
Adipocyte-derived PDGF-D counteracts age-associated obesity through ameliorating lymphatic function
Normal lymphatic function protects against obesity by preventing abnormal lymph leakage, which drives excessive adipocyte proliferation in adjacent tissues. Notably, platelet-derived growth factor D (PDGF-D) has been reported to play key roles in lymphangiogenesis. However, whether PDGF-D regulates age-associated obesity through modulation of lymphatic function remains unknown. In the study, we found that middle-aged mice exhibited greater susceptibility to high-fat diet (HFD)-induced obesity than young mice, accompanied by reduced lymphatic vessel density, impaired lymphatic function, and decreased PDGF-D expression in adipose tissue. By generating adipocyte-specific PDGF-D knockout and overexpression mice, we demonstrated that PDGF-D deficiency, despite having no direct effect on adipocytes, was sufficient to induce lymphatic dysfunction, which in turn exacerbated HFD-induced obesity in young mice. While adipocyte-specific PDGF-D overexpression restored lymphatic function and reversed HFD-induced severe obesity in middle-aged mice. Moreover, stimulating lymphangiogenesis via adeno-associated virus (AAV)-mediated delivery of an engineered VEGF-C variant (VEGF-C156S) successfully suppressed HFD-induced obesity in young adipocyte-PDGF-D knockout mice. In vitro , we found that adipocyte-derived PDGF-D promoted tube formation, proliferation, and the integrity of lymphatic endothelial cells (LECs), thereby preventing lipid permeation and subsequently suppressing adipogenesis. In conclusion, these findings demonstrate an uncovered mechanism by which adipocyte-derived PDGF-D protects against age-related obesity through regulation of lymphatic function.
- 4 November 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1963378
Open AccessAdipocyte-derived PDGF-D counteracts age-associated obesity through ameliorating lymphatic function
Normal lymphatic function protects against obesity by preventing abnormal lymph leakage, which drives excessive adipocyte proliferation in adjacent tissues. Notably, platelet-derived growth factor D (PDGF-D) has been reported to play key roles in lymphangiogenesis. However, whether PDGF-D regulates age-associated obesity through modulation of lymphatic function remains unknown. In the study, we found that middle-aged mice exhibited greater susceptibility to high-fat diet (HFD)-induced obesity than young mice, accompanied by reduced lymphatic vessel density, impaired lymphatic function, and decreased PDGF-D expression in adipose tissue. By generating adipocyte-specific PDGF-D knockout and overexpression mice, we demonstrated that PDGF-D deficiency, despite having no direct effect on adipocytes, was sufficient to induce lymphatic dysfunction, which in turn exacerbated HFD-induced obesity in young mice. While adipocyte-specific PDGF-D overexpression restored lymphatic function and reversed HFD-induced severe obesity in middle-aged mice. Moreover, stimulating lymphangiogenesis via adeno-associated virus (AAV)-mediated delivery of an engineered VEGF-C variant (VEGF-C156S) successfully suppressed HFD-induced obesity in young adipocyte-PDGF-D knockout mice. In vitro , we found that adipocyte-derived PDGF-D promoted tube formation, proliferation, and the integrity of lymphatic endothelial cells (LECs), thereby preventing lipid permeation and subsequently suppressing adipogenesis. In conclusion, these findings demonstrate an uncovered mechanism by which adipocyte-derived PDGF-D protects against age-related obesity through regulation of lymphatic function.
- Open Access
- 7 July 2026
- Published by Wolters Kluwer Health in Circulation Research
B1a Cell-IgM Axis Protects Against Hypertension by Blunting IFNγ+CD4+T Cells
BACKGROUND: Innate and adaptive immune cells play important roles in the pathogenesis of hypertension. B cells play a crucial role in mammalian adaptive immunity via processing antigens and producing antibodies. However, whether B cells and immunoglobulins are involved in regulating blood pressure in hypertension remains unclear. We aimed to reveal the protective role and the potential immunoregulatory mechanisms of B1a cells in hypertension. METHODS: Wild-type and CD19 knockout (CD19 −/− ) mice received angiotensin II (Ang II) to induce hypertension. Blood pressure measured by radiotelemetry and tail cuff. Vascular damage was assessed by histology and immunofluorescence. Immune cells were analyzed by flow cytometry. Adoptive transfer of different B-cell subsets was performed. In vitro cocultures examined B1a cell effects on CD4+T cells. RESULTS: We found that the frequency of B1a cells was reduced in the blood and peritoneal cavity in wild-type mice after Ang II infusion. We showed that CD19 −/− male mice, which exhibit a marked reduction in B1a cells, largely exacerbated the elevation of both systolic and diastolic blood pressures after Ang II treatment compared with wild type. Vascular dysfunction and damage, including CD4+T cells and macrophage accumulation, aortic structural remodeling, and fibrosis, were worse in CD19 −/− male mice compared with wild-type male mice in response to Ang II. Adoptive transfer of B1a cells, but not B2 cells, protected against Ang II-induced hypertension and vascular damage. The serum level of IgM was reduced in CD19 −/− mice but increased after transferring with B1a cells. In vitro, B1a cells and natural IgM inhibited the activation and IFNγ (interferon gamma) production of CD4+T cells. Furthermore, transferring B1a cells deficient in the secretion of IgM blocked the protective effects in response to Ang II infusion. CONCLUSIONS: Our data demonstrated that B1a cells play a protective role in the development of hypertension via producing natural IgM and inhibiting IFNγ production by CD4+T cells.
- 7 July 2026
- Published by Wolters Kluwer Health in Circulation Research
Open AccessB1a Cell-IgM Axis Protects Against Hypertension by Blunting IFNγ+CD4+T Cells
BACKGROUND: Innate and adaptive immune cells play important roles in the pathogenesis of hypertension. B cells play a crucial role in mammalian adaptive immunity via processing antigens and producing antibodies. However, whether B cells and immunoglobulins are involved in regulating blood pressure in hypertension remains unclear. We aimed to reveal the protective role and the potential immunoregulatory mechanisms of B1a cells in hypertension. METHODS: Wild-type and CD19 knockout (CD19 −/− ) mice received angiotensin II (Ang II) to induce hypertension. Blood pressure measured by radiotelemetry and tail cuff. Vascular damage was assessed by histology and immunofluorescence. Immune cells were analyzed by flow cytometry. Adoptive transfer of different B-cell subsets was performed. In vitro cocultures examined B1a cell effects on CD4+T cells. RESULTS: We found that the frequency of B1a cells was reduced in the blood and peritoneal cavity in wild-type mice after Ang II infusion. We showed that CD19 −/− male mice, which exhibit a marked reduction in B1a cells, largely exacerbated the elevation of both systolic and diastolic blood pressures after Ang II treatment compared with wild type. Vascular dysfunction and damage, including CD4+T cells and macrophage accumulation, aortic structural remodeling, and fibrosis, were worse in CD19 −/− male mice compared with wild-type male mice in response to Ang II. Adoptive transfer of B1a cells, but not B2 cells, protected against Ang II-induced hypertension and vascular damage. The serum level of IgM was reduced in CD19 −/− mice but increased after transferring with B1a cells. In vitro, B1a cells and natural IgM inhibited the activation and IFNγ (interferon gamma) production of CD4+T cells. Furthermore, transferring B1a cells deficient in the secretion of IgM blocked the protective effects in response to Ang II infusion. CONCLUSIONS: Our data demonstrated that B1a cells play a protective role in the development of hypertension via producing natural IgM and inhibiting IFNγ production by CD4+T cells.
- 17 January 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 246, 196-208
Orientin alleviates severe inflammation via regulating macrophage glycolysis and immune function in sepsis
- 17 January 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 246, 196-208
Orientin alleviates severe inflammation via regulating macrophage glycolysis and immune function in sepsis
- 8 June 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 161, 115033
Targeting notch1 with berbamine alleviates the inflammatory responses of macrophages in sepsis
- 8 June 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 161, 115033
Targeting notch1 with berbamine alleviates the inflammatory responses of macrophages in sepsis
- Open Access
- 8 July 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (9)
PDGF-D activation by macrophage-derived uPA promotes AngII-induced cardiac remodeling in obese mice
Obesity-induced secretory disorder of adipose tissue–derived factors is important for cardiac damage. However, whether platelet-derived growth factor-D (PDGF-D), a newly identified adipokine, regulates cardiac remodeling in angiotensin II (AngII)–infused obese mice is unclear. Here, we found obesity induced PDGF-D expression in adipose tissue as well as more severe cardiac remodeling compared with control lean mice after AngII infusion. Adipocyte-specific PDGF-D knockout attenuated hypertensive cardiac remodeling in obese mice. Consistently, adipocyte-specific PDGF-D overexpression transgenic mice (PA-Tg) showed exacerbated cardiac remodeling after AngII infusion without high-fat diet treatment. Mechanistic studies indicated that AngII-stimulated macrophages produce urokinase plasminogen activator (uPA) that activates PDGF-D by splicing full-length PDGF-D into the active PDGF-DD. Moreover, bone marrow–specific uPA knockdown decreased active PDGF-DD levels in the heart and improved cardiac remodeling in HFD hypertensive mice. Together, our data provide for the first time a new interaction pattern between macrophage and adipocyte: that macrophage-derived uPA activates adipocyte-secreted PDGF-D, which finally accelerates AngII-induced cardiac remodeling in obese mice.
- 8 July 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (9)
Open AccessPDGF-D activation by macrophage-derived uPA promotes AngII-induced cardiac remodeling in obese mice
Obesity-induced secretory disorder of adipose tissue–derived factors is important for cardiac damage. However, whether platelet-derived growth factor-D (PDGF-D), a newly identified adipokine, regulates cardiac remodeling in angiotensin II (AngII)–infused obese mice is unclear. Here, we found obesity induced PDGF-D expression in adipose tissue as well as more severe cardiac remodeling compared with control lean mice after AngII infusion. Adipocyte-specific PDGF-D knockout attenuated hypertensive cardiac remodeling in obese mice. Consistently, adipocyte-specific PDGF-D overexpression transgenic mice (PA-Tg) showed exacerbated cardiac remodeling after AngII infusion without high-fat diet treatment. Mechanistic studies indicated that AngII-stimulated macrophages produce urokinase plasminogen activator (uPA) that activates PDGF-D by splicing full-length PDGF-D into the active PDGF-DD. Moreover, bone marrow–specific uPA knockdown decreased active PDGF-DD levels in the heart and improved cardiac remodeling in HFD hypertensive mice. Together, our data provide for the first time a new interaction pattern between macrophage and adipocyte: that macrophage-derived uPA activates adipocyte-secreted PDGF-D, which finally accelerates AngII-induced cardiac remodeling in obese mice.
- Open Access
- 15 October 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-13
Cardioprotective Natural Compound Pinocembrin Attenuates Acute Ischemic Myocardial Injury via Enhancing Glycolysis
Purpose. Emerging evidence has shown that pinocembrin protects the myocardium from ischemic injury in animals. However, it is unknown whether it has cardioprotection when given at the onset of reperfusion. Also, mechanisms mediating the cardioprotective actions of pinocembrin were largely unknown. Thus, this study is aimed at investigating the effects of pinocembrin postconditioning on ischemia-reperfusion (I/R) injury and the underlying mechanisms. Methods. The in vivo mouse model of myocardial I/R injury, ex vivo isolated rat heart with global I/R, and in vitro hypoxia/reoxygenation (H/R) injury model for primary cardiomyocytes were used. Results. We found that pinocembrin postconditioning significantly reduced the infarct size and improved cardiac contractile function after acute myocardial I/R. Mechanically, in primary cardiomyocytes, we found that pinocembrin may confer protection in part via direct stimulation of cardiac glycolysis via promoting the expression of the glycolytic enzyme, PFKFB3. Besides, PFKFB3 inhibition abolished pinocembrin-induced glycolysis and protection in cardiomyocytes. More importantly, PFKFB3 knockdown via cardiotropic adeno-associated virus (AAV) abrogated cardioprotective effects of pinocembrin. Moreover, we demonstrated that HIF1α is a key transcription factor driving pinocembrin-induced PFKFB3 expression in cardiomyocytes. Conclusions. In conclusion, these results established that the acute cardioprotective benefits of pinocembrin are mediated in part via enhancing PFKFB3-mediated glycolysis via HIF1α, which may provide a new therapeutic target to impede the progression of myocardial I/R injury.
- 15 October 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-13
Open AccessCardioprotective Natural Compound Pinocembrin Attenuates Acute Ischemic Myocardial Injury via Enhancing Glycolysis
Purpose. Emerging evidence has shown that pinocembrin protects the myocardium from ischemic injury in animals. However, it is unknown whether it has cardioprotection when given at the onset of reperfusion. Also, mechanisms mediating the cardioprotective actions of pinocembrin were largely unknown. Thus, this study is aimed at investigating the effects of pinocembrin postconditioning on ischemia-reperfusion (I/R) injury and the underlying mechanisms. Methods. The in vivo mouse model of myocardial I/R injury, ex vivo isolated rat heart with global I/R, and in vitro hypoxia/reoxygenation (H/R) injury model for primary cardiomyocytes were used. Results. We found that pinocembrin postconditioning significantly reduced the infarct size and improved cardiac contractile function after acute myocardial I/R. Mechanically, in primary cardiomyocytes, we found that pinocembrin may confer protection in part via direct stimulation of cardiac glycolysis via promoting the expression of the glycolytic enzyme, PFKFB3. Besides, PFKFB3 inhibition abolished pinocembrin-induced glycolysis and protection in cardiomyocytes. More importantly, PFKFB3 knockdown via cardiotropic adeno-associated virus (AAV) abrogated cardioprotective effects of pinocembrin. Moreover, we demonstrated that HIF1α is a key transcription factor driving pinocembrin-induced PFKFB3 expression in cardiomyocytes. Conclusions. In conclusion, these results established that the acute cardioprotective benefits of pinocembrin are mediated in part via enhancing PFKFB3-mediated glycolysis via HIF1α, which may provide a new therapeutic target to impede the progression of myocardial I/R injury.
- 25 October 2016
- Vol. 68 (5) , 669-676
Mitochondrial division inhibitor Mdivi-1 ameliorates angiotensin II-induced endothelial dysfunction.
Mitochondrial fission can occur via activation of dynamin-related protein 1 (Drp1), which participates in the mitochondrial membrane scission process. The present study was designed to investigate the effect of angiotensin II (AngII) on mitochondrial fission and fusion in human umbilical vascular endothelial cells (HUVECs). And we further inquire into whether Mdivi-1, a newly identified pharmacological inhibitor of Drp1, can prevent endothelial dysfunction induced by AngII. The HUVECs were treated with AngII alone or in combination with Mdivi-1. Western blot was used to detect protein expressions of Drp1, endothelial nitric oxide synthase (eNOS) and apoptosis-related enzymes. MitoTracker Red and JC-1 dye were used to detect mitochondrial morphology and membrane potential, respectively. DCFH-DA probe was used to access intracellular reactive oxygen species (ROS) generation. Transwell assay was used to evaluate cell migration. Annexin V/PI staining was used to assess cellular apoptosis. The results showed that, in cultured HUVECs, AngII (1 × 10-7 mol/L, 12 h) treatment significantly upregulated the expression of Drp1 followed by increased apoptosis and decreased eNOS expression. The treatment of AngII resulted in a change in mitochondrial morphology from elongated to uniformly punctate organelles, which was accompanied by decreased mitochondrial membrane potential. Furthermore, Mdivi-1 significantly protected against AngII-induced endothelial dysfunction, as shown by increased mitochondrial membrane potential and eNOS expression, reduced ROS level, decreased apoptosis and migration ability. Taking together, our data suggest that inhibition of Drp1 with Mdivi-1 can restore AngII-induced endothelial dysfunction.
- 25 October 2016
- Vol. 68 (5) , 669-676
Mitochondrial division inhibitor Mdivi-1 ameliorates angiotensin II-induced endothelial dysfunction.
Mitochondrial fission can occur via activation of dynamin-related protein 1 (Drp1), which participates in the mitochondrial membrane scission process. The present study was designed to investigate the effect of angiotensin II (AngII) on mitochondrial fission and fusion in human umbilical vascular endothelial cells (HUVECs). And we further inquire into whether Mdivi-1, a newly identified pharmacological inhibitor of Drp1, can prevent endothelial dysfunction induced by AngII. The HUVECs were treated with AngII alone or in combination with Mdivi-1. Western blot was used to detect protein expressions of Drp1, endothelial nitric oxide synthase (eNOS) and apoptosis-related enzymes. MitoTracker Red and JC-1 dye were used to detect mitochondrial morphology and membrane potential, respectively. DCFH-DA probe was used to access intracellular reactive oxygen species (ROS) generation. Transwell assay was used to evaluate cell migration. Annexin V/PI staining was used to assess cellular apoptosis. The results showed that, in cultured HUVECs, AngII (1 × 10-7 mol/L, 12 h) treatment significantly upregulated the expression of Drp1 followed by increased apoptosis and decreased eNOS expression. The treatment of AngII resulted in a change in mitochondrial morphology from elongated to uniformly punctate organelles, which was accompanied by decreased mitochondrial membrane potential. Furthermore, Mdivi-1 significantly protected against AngII-induced endothelial dysfunction, as shown by increased mitochondrial membrane potential and eNOS expression, reduced ROS level, decreased apoptosis and migration ability. Taking together, our data suggest that inhibition of Drp1 with Mdivi-1 can restore AngII-induced endothelial dysfunction.